Bruno Piras

Bruno Piras

Auto-generated profile, based on publicly available information

Bruno Piras

Struttura Semplice Dipartimentale di Emergenze in Ostetricia e Ginecologia Azienda Ospedaliero Universitaria Cagliari–Policlinico Duilio Casula Monserrato Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2019 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
Manuela NeriManuela Neri
Manuela Neri
MPMichele Peiretti
Michele Peiretti
GMGian Benedetto Melis
Gian Benedetto Melis
BPBruno Piras
Bruno Piras
VVValerio Vallerino
Valerio Vallerino
Valerio MaisValerio Mais
Valerio Mais
Introduction: Endometrial cancer (EC) is one of the most frequent gynecological cancers worldwide. The gold standard treatment of EC is most certainly surgery and may very well be the only therapy in the early stages of disease. To improve outcomes in non-early EC, adjuvant therapy is often employed but this is not standardized. Adjuvant options can include radiotherapy, chemotherapy or a combination of both. Adjuvant chemotherapy could be indicated in high-risk stage I and II or advanced stage EC. Several clinical trials are ongoing in an attempt to define the optimal adjuvant treatment. Furthermore, chemotherapy is the front-line therapy in advanced unresectable, metastatic or recurrent endometrial cancer. Areas covered: Herein, the authors review the first-line chemotherapy for the treatment of endometrial cancer and provide their expert perspectives on these therapies. Expert opinion: Chemotherapy is fundamental in advanced/recurrent EC. Further evidence is needed to characterize the role of adjuvant chemotherapy. Future studies should consider genomic and molecular heterogeneities to identify even more efficient tailored therapies.

26 April 2018 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
GMGian Benedetto Melis
Gian Benedetto Melis
Manuela NeriManuela Neri
Manuela Neri
BPBruno Piras
Bruno Piras
APAnna Maria Paoletti
Anna Maria Paoletti
SASilvia Ajossa
Silvia Ajossa
Valerio MaisValerio Mais
Valerio Mais
Introduction: The medical strategy to antagonize myoma size and related-symptoms is to reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH agonist (GnRHa) or with compounds that antagonize progesterone stimulatory activity on myomas. Selective progesterone receptor modulators (SPRMs) bind progesterone receptor (PR), leading to both agonist and antagonist effects. The result of SPRMs’s action is tissue-specific and it depends on the particular affinity and strength of each SPRM. Area covered: Ulipristal acetate (UPA) is the first SPRM registered for myoma treatment. UPA reduces heavy uterine bleeding within 7 days from the onset of treatment, whereas a longer time is required with GnRHa treatment. Vilaprisan is a novel powerful SPRM. Phase I and II studies give encouraging results on the efficacy of vilaprisan at different doses. Like other SPRMs, vilaprisan induces benign changes of endometrium (PR modulator-associated endometrial changes, PAECs). These disappear as treatment is discontinued. Unlike GnRHa treatment, neither UPA nor vilaprisan induce hypoestrogenism and associated symptoms. Phase III studies are ongoing to confirm efficacy and safety of vilaprisan in long-term treatment of symptomatic fibroids. Expert opinion: It is fundamental to underline the rapidity of action (only 3 days) in the control of myoma-related bleeding.

12 April 2018 in Gynecological Endocrinology
Verified
Journal Article
Closed access
GMGian Benedetto Melis
Gian Benedetto Melis
BPBruno Piras
Bruno Piras
MMMaria Francesca Marotto
Maria Francesca Marotto
Manuela NeriManuela Neri
Manuela Neri
VCValentina Corda
Valentina Corda
Valerio MaisValerio Mais
Valerio Mais
The vaginal immune system (VIS) is the first defense against antigens recognized as foreign. Substances capable of locally activating the VIS could be a valid strategy to treat vulvo-vaginal infections (VVI), caused by changes in the vaginal ecosystem, such as bacterial vaginosis (BV), vulvo-vaginal candidiasis (CA), and mixed vaginitis (MV). Bacterial lysates, obtained by crushing bacterial cultures, exert immuno-modulatory activities. The parietal fraction from Propionibacterium acnes is a patent of Depofarma (MoglianoVeneto, Italy). The preparation that associates such fraction to hyaluronic acid and polycarbophil is a registered trademark, commercially available in Italy as vaginal gel, Immunovag®. The study aimed to evaluate whether a 5-day-treatment with Immunovag® improves the symptoms and signs of VVI, in 60 women with Gardnerella vaginalis (GV), 154 with CA, 95 with MV, diagnosed with vulvar vaginal swab (VVS), and in 283 with BV, diagnosed with the Amsel criteria. At the end of the treatment (visit 2), the symptoms and signs of VVI disappeared in a significant number of subjects (χ2p < .02 vs pre-treatment) in all VVI groups, and their intensity was significantly (p < .0002) reduced in the subjects in which they were still present. Immunovag® represents a valid treatment of VVI induced by changes in the vaginal ecosystem.

1 March 2019 in Gynecological Endocrinology
Verified
Journal Article
Closed access
Manuela NeriManuela Neri
Manuela Neri
MPMonica Pilloni
Monica Pilloni
APAnna Maria Paoletti
Anna Maria Paoletti
GMGian Benedetto Melis
Gian Benedetto Melis
BPBruno Piras
Bruno Piras
Valerio MaisValerio Mais
Valerio Mais
This observational study was conducted in premenopausal women who presented themselves at the Obstetrics and Gynecology Department of the University Hospital of Cagliari (Italy), for heavy menstrual bleeding (HMB) dependent on uterine myomas. After a screening visit, 19 women without contraindications to ulipristal acetate (UPA) treatment, were included in the study that envisaged 12 months of observation in which each subject was asked to assume UPA (tablet of 5 mg, ESMYA®, one tablet a day for 3 months: first cycle) two menstrual cycles of interruption and a second ESMYA® cycle, followed by 3 months of observation (third follow-up month, visit 4). The significant decrease of myoma volume, diagnosed after the first ESMYA® cycle, persisted until the visit 4. The HMB significantly decreased during the ESMYA® treatment and persisted until visit 4. The quality of life (QoL), evaluated with the questionnaire SF-36, significantly improved during the study. The values of estradiol (E2), biochemical parameters of bone metabolism, as well as those of lumbar and hip bone mineral density, did not change during the study in comparison with basal levels. The efficacy of two repeated ESMYA® cycles to treat uterine myomas and their related symptoms improves the QoL without interfering with bone health.

4 March 2024 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
SGStefano Guerriero
Stefano Guerriero
BPB. Piras
B. Piras
MRM. L. Robuschi
M. L. Robuschi
LSL. Suzzi
L. Suzzi
SAS. Ajossa
S. Ajossa